医学
罗哌卡因
麻醉
左旋布比卡因
不利影响
安慰剂
止痛药
曲马多
随机对照试验
外科
吗啡
类阿片
腰椎
渗透(HVAC)
安慰剂对照研究
生理盐水
临床试验
局部麻醉剂
手术伤口
羟考酮
丸(消化)
作者
Samuel Haupt,Christoph J. Laux,Steven M. Maurer,Farah Selman,Alexander Lebeda,Stefani Dossi,Tobias Götschi,Sabrina Catanzaro,Hagen Bomberg,Urs Eichenberger,Mazda Farshad
标识
DOI:10.1016/j.spinee.2026.04.012
摘要
BACKGROUND: Effective postoperative pain control remains a major challenge in spine surgery. Local wound infiltration with anesthetics is a simple component of multimodal analgesia, yet high-quality comparative data between different infiltration regimens are limited. PURPOSE: To evaluate the analgesic efficacy and safety of ropivacaine and levobupivacaine/tramadol wound infiltration compared with placebo in lumbar spine surgery. STUDY DESIGN/SETTING: Prospective, randomized, double-blind, controlled clinical trial. PATIENT SAMPLE: A total of 125 patients undergoing elective primary or revision lumbar spine surgery. OUTCOME MEASURES: Postoperative pain intensity (VAS 2-12 hours), opioid consumption (24 hours), length of hospital stay, sick leave, and adverse events. METHODS: Patients were randomized to receive intraoperative epifascial and subcutaneous wound infiltration with either 0.9% saline (placebo), 0.75% ropivacaine, or 0.5% levobupivacaine+tramadol (100 mg). Outcomes were analyzed using mixed-effects linear models and nonparametric tests. RESULTS: There were no significant differences in postoperative pain scores or opioid consumption between treatment groups at any time point. Hospital stay and functional recovery were comparable. Sick leave duration was shorter in the ropivacaine group compared with placebo (p=.021). No infiltration-related adverse events occurred. CONCLUSIONS: Local wound infiltration with ropivacaine or levobupivacaine/tramadol is safe but does not provide a clinically meaningful benefit in early postoperative pain control or opioid reduction after lumbar spine surgery. Broader multimodal strategies may be required to achieve optimal postoperative recovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI